Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -46.15% | -37.49% | -67.00% | -17.64% |
| EV / EBITDA | -2.64 | -9.67 | -3.58 | -0.34 |
| Quality | ||||
| ROIC | 127.33% | 96.18% | -115.63% | 1,188.09% |
| Gross Margin | 0.00% | -321.68% | -703.67% | -2,019.31% |
| Cash Conversion Ratio | 1.87 | 1.09 | 1.09 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.57% | -28.08% | -19.84% | 5.18% |
| Free Cash Flow Growth | 13.57% | 0.91% | -53.33% | 52.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.80 | -4.56 | -2.06 | -0.05 |
| Interest Coverage | 0.00 | -1.90 | -5.37 | -14.70 |
| Efficiency | ||||
| Inventory Turnover | 1.68 | 0.00 | 0.26 | 0.83 |
| Cash Conversion Cycle | -333.96 | -61,675.73 | -156.51 | 1,041.92 |